{
  "items": "40",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT",
      "url": "https://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-invests-331-million-in-immunovant-inc-imvt-2025-12-23/",
      "time_published": "20251223T080943",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Assenagon Asset Management S.A. has invested $3.31 million in Immunovant, Inc. ($IMVT), acquiring 205,219 shares and establishing a new position in the company. Institutional investors now own 47.08% of Immunovant, while company insiders have been net sellers, offloading shares worth approximately $1.60 million in the last 90 days. The stock currently holds a \"Moderate Buy\" rating from analysts with an average price target of $27.63.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.945168"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.849477"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.900958"
        },
        {
          "topic": "finance",
          "relevance_score": "0.747270"
        }
      ],
      "overall_sentiment_score": 0.250042,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.284533",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/how-investors-are-reacting-to-immunovant-imvt-550-million-fo/amp",
      "time_published": "20251222T200927",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immunovant recently completed a significant $550.2 million equity offering, issuing 26,200,000 common shares at $21 each, substantially increasing its financial resources but also diluting existing shareholders. This capital raise aims to fund upcoming trials and launches, while the company's investment narrative now balances funding strength with dilution and governance concerns. The article highlights that despite the new capital, core clinical and dilution risks remain, with one valuation suggesting the shares might be trading at a premium.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.911437"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.844197"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.741631"
        }
      ],
      "overall_sentiment_score": -0.255919,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.281216",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Squarepoint Ops LLC Has $1.36 Million Stock Position in Immunovant, Inc. $IMVT",
      "url": "https://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-has-136-million-stock-position-in-immunovant-inc-imvt-2025-12-20/",
      "time_published": "20251220T050933",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Squarepoint Ops LLC significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 714.6% in the second quarter, bringing its total holdings to 84,919 shares valued at approximately $1.36 million. Immunovant is trading near its 12-month high with a market capitalization of $4.68 billion, and analysts generally rate it as a \"Moderate Buy\" with a consensus price target of $27.63. Despite institutional ownership of 47.08%, insiders have recently sold shares, reducing their ownership to 1.8%.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.912745"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.841446"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.740785"
        },
        {
          "topic": "finance",
          "relevance_score": "0.631528"
        }
      ],
      "overall_sentiment_score": 0.118165,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.115563",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.607066",
          "ticker_sentiment_score": "0.131647",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.579172",
          "ticker_sentiment_score": "0.100886",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tuyl Christopher Van Sells 10,813 Shares of Immunovant (NASDAQ:IMVT) Stock",
      "url": "https://www.marketbeat.com/instant-alerts/tuyl-christopher-van-sells-10813-shares-of-immunovant-nasdaqimvt-stock-2025-12-19/",
      "time_published": "20251219T220856",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Tuyl Christopher Van, an insider at Immunovant (NASDAQ:IMVT), sold 10,813 shares of the company's stock on December 18th for approximately $290,978, reducing his stake by 6.73%. The biotech company's stock closed at $26.68 on Friday with high trading volume and a market capitalization of $4.68 billion. Immunovant recently missed analyst EPS estimates and currently holds a \"Moderate Buy\" consensus rating from analysts with an average target price of $27.63.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908831"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.809142"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.720718"
        },
        {
          "topic": "finance",
          "relevance_score": "0.622146"
        }
      ],
      "overall_sentiment_score": -0.2092,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.241171",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?",
      "url": "https://finance.yahoo.com/news/immunovant-stock-buy-roivant-sciences-075509310.html",
      "time_published": "20251219T060927",
      "authors": [
        "Robert Izquierdo",
        "The Motley Fool"
      ],
      "summary": "Roivant Sciences Ltd. recently increased its stake in Immunovant (NASDAQ:IMVT) by acquiring 16,666,666 shares for approximately $350 million. This significant purchase, made at a discount to the market price, increases Roivant's direct ownership to over 64% of Immunovant's outstanding shares. The investment aims to fund Immunovant's medical research and clinical trials for its lead drug candidate, IMVT-1402, making Immunovant a high-risk, high-reward prospect dependent on favorable trial results and FDA approval.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/PJ0bieE00kaRNNlQCqqc6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE4MjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2020-10/515f50a0-0f30-11eb-9ebf-0273aacc9ef0",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.930893"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.801460"
        },
        {
          "topic": "finance",
          "relevance_score": "0.722419"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.633717"
        }
      ],
      "overall_sentiment_score": 0.025238,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.324792",
          "ticker_sentiment_score": "0.003375",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed?",
      "url": "https://finance.yahoo.com/news/immunovant-imvt-14-0-roivant-190944582.html",
      "time_published": "20251215T110900",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immunovant recently secured a $550.20 million equity raise, including a significant commitment from controlling shareholder Roivant Sciences, to fund the development and potential commercial launch of its lead candidate, IMVT-1402. This financing significantly reduces the company's near-term cash operational risks but shifts investor focus towards execution risks associated with multiple late-stage trials and ongoing operational losses. While diluting existing holders, the capital raise strengthens the path for clinical data and regulatory progress for IMVT-1402, an important consideration for investors monitoring Immunovant's investment narrative.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936818"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.819362"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.729907"
        }
      ],
      "overall_sentiment_score": 0.32418,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.341756",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets",
      "url": "https://ts2.tech/en/immunovant-imvt-stock-news-and-forecast-for-dec-14-2025-550m-financing-closes-roivant-buys-350m-analysts-update-targets/",
      "time_published": "20251214T070930",
      "authors": [
        "Khadija Saeed"
      ],
      "summary": "Immunovant (IMVT) completed a $550 million common stock financing, with its controlling shareholder, Roivant Sciences, purchasing $350 million worth of shares. This capital raise, intended to fund Immunovant's autoimmune pipeline, resulted in significant share dilution but reduces financing risk. Analysts have updated their price targets, and the company's pipeline has key readouts expected in 2026 and 2027.",
      "banner_image": null,
      "source": "ts2.tech",
      "category_within_source": "General",
      "source_domain": "ts2.tech",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.900092"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.940384"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.703265"
        }
      ],
      "overall_sentiment_score": 0.005797,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.341736",
          "ticker_sentiment_score": "0.044029",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant, Inc. $IMVT is Armistice Capital LLC's 9th Largest Position",
      "url": "https://www.marketbeat.com/instant-alerts/filing-immunovant-inc-imvt-is-armistice-capital-llcs-9th-largest-position-2025-12-12/",
      "time_published": "20251213T070930",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Armistice Capital LLC reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by 3.7%, selling 200,000 shares but retaining 5.2 million shares valued at $83.2 million, making it their 9th largest holding. Immunovant shares opened at $24.81, with analysts giving a \"Moderate Buy\" rating and a consensus price target of $28.78. Insiders have sold 57,847 shares in the last quarter, while institutional investors own 47.08% of the stock.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923663"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843207"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.726357"
        },
        {
          "topic": "finance",
          "relevance_score": "0.615609"
        }
      ],
      "overall_sentiment_score": 0.070658,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.089667",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Owner Roivant Sciences Ltd Buys 16,666,666 ($350M) Of Immunovant Inc [IMVT]",
      "url": "https://www.tradingview.com/news/reuters.com,2025-12-12:newsml_WSABVDhTa:0-owner-roivant-sciences-ltd-buys-16-666-666-350m-of-immunovant-inc-imvt/",
      "time_published": "20251213T070843",
      "authors": [
        "Refinitiv"
      ],
      "summary": "Roivant Sciences Ltd, a beneficial owner of Immunovant Inc (IMVT), filed a Form 4 on December 12, 2025, detailing a significant purchase. The company acquired 16,666,666 shares of Immunovant at a price of $21.00 per share, totaling nearly $350 million. This transaction increased Roivant Sciences Ltd's direct holdings to 113,317,007 shares.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.919770"
        },
        {
          "topic": "finance",
          "relevance_score": "0.815243"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725152"
        }
      ],
      "overall_sentiment_score": 0.339978,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.344365",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m",
      "url": "https://www.investing.com/news/insider-trading-news/roivant-sciences-buys-immunovant-imvt-shares-worth-3499m-93CH-4406887",
      "time_published": "20251212T220859",
      "authors": [
        "NULL"
      ],
      "summary": "Roivant Sciences Ltd., a major stakeholder in Immunovant, Inc. (NASDAQ:IMVT), recently acquired 16,666,666 shares for approximately $350 million. This transaction occurred at a price of $21.0 per share, which is a significant discount compared to the current trading price of $26.43. Immunovant, a biotech company with a $4.61 billion market cap, also announced a $550 million stock offering, with Roivant agreeing to participate, to fund its operations and the potential commercial launch of IMVT-1402.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.936456"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843122"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.712601"
        }
      ],
      "overall_sentiment_score": 0.041438,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.301089",
          "ticker_sentiment_score": "0.024881",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant Enters Underwriting Agreement for Stock Offering",
      "url": "https://www.tradingview.com/news/tradingview:bc0eec92163be:0-immunovant-enters-underwriting-agreement-for-stock-offering/",
      "time_published": "20251212T210859",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant, Inc. announced an underwritten offering of 26.2 million shares priced at $21.00 each, raising $550 million in gross proceeds. Roivant Sciences Ltd. participated in the offering, which closed on December 12, 2025.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904503"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.839406"
        }
      ],
      "overall_sentiment_score": 0.116027,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.130634",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant announces $550 million stock offering",
      "url": "https://www.msn.com/en-us/money/savingandinvesting/immunovant-announces-550-million-stock-offering/ar-AA1S9ZK8",
      "time_published": "20251212T080859",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant has announced a stock offering aiming to raise $550 million. This move is intended to secure additional funding, likely for its ongoing operations, research, and development projects.",
      "banner_image": "NULL",
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.834538"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.747018"
        },
        {
          "topic": "finance",
          "relevance_score": "0.606174"
        }
      ],
      "overall_sentiment_score": 0.110304,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.142338",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant Announces Pricing of $550 Million Common Stock Financing",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMVT/pressreleases/36564511/immunovant-announces-pricing-of-550-million-common-stock-financing/",
      "time_published": "20251212T070930",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant, Inc. announced the pricing of an underwritten offering of its common stock, expecting to raise approximately $550 million in gross proceeds. Roivant Sciences Ltd. will purchase shares in the offering. The financing aims to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves\u2019 Disease.",
      "banner_image": "https://barchart-news-media-prod.aws.barchart.com/GLOBENW_TGAM/7c12c1057105ffddac1f4dc87d212060/immulogo-jpg.jpg",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.901081"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.827090"
        }
      ],
      "overall_sentiment_score": 0.208371,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.205187",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Latham & Watkins Advises on Immunovant\u2019s US$550 Million Offering of Common Stock",
      "url": "https://www.lw.com/en/news/2025/12/latham-watkins-advises-on-immunovant-offering-of-common-stock",
      "time_published": "20251212T020946",
      "authors": [
        "NULL"
      ],
      "summary": "Latham & Watkins LLP advised the underwriter in Immunovant, Inc.'s offering of common stock, which is expected to generate gross proceeds of approximately US$550 million. Immunovant, a clinical-stage immunology company, offered 26.2 million shares at US$21 per share. The offering is anticipated to close around December 12, 2025.",
      "banner_image": "https://contenthub.lw.com/api/public/content/525cabdce2a1414a83e59c020cbea88d?v=f0b8094c&t=750x225",
      "source": "Latham & Watkins LLP",
      "category_within_source": "General",
      "source_domain": "Latham & Watkins LLP",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.848256"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.749553"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.916965"
        }
      ],
      "overall_sentiment_score": 0.340315,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.343815",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immunovant Announces Pricing of $550 Million Common Stock Financing",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMVT-Q/pressreleases/36564511/immunovant-announces-pricing-of-550-million-common-stock-financing/",
      "time_published": "20251211T122900",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant, Inc. announced the pricing of an underwritten offering of its common stock, expecting to raise approximately $550 million in gross proceeds. The funding, including a purchase by controlling stockholder Roivant Sciences Ltd., is intended to support the company's operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves' Disease. Immunovant offered 26.2 million shares at $21.00 per share, with Leerink Partners acting as the sole underwriter.",
      "banner_image": "https://barchart-news-media-prod.aws.barchart.com/GLOBENW_TGAM/7c12c1057105ffddac1f4dc87d212060/immulogo-jpg.jpg",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936212"
        },
        {
          "topic": "finance",
          "relevance_score": "0.722000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.623424"
        }
      ],
      "overall_sentiment_score": 0.409798,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.409645",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immunovant Announces Pricing of $550 Million Common Stock Financing",
      "url": "https://www.manilatimes.net/2025/12/11/tmt-newswire/globenewswire/immunovant-announces-pricing-of-550-million-common-stock-financing/2241352",
      "time_published": "20251211T070933",
      "authors": [
        "GlobeNewswire"
      ],
      "summary": "Immunovant, Inc. announced the pricing of an underwritten offering of its common stock, anticipating gross proceeds of approximently $550 million. This financing is expected to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves\u2019 Disease. Roivant Sciences Ltd., the controlling stockholder, has agreed to purchase shares in the offering.",
      "banner_image": "NULL",
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.900021"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.846563"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.718961"
        }
      ],
      "overall_sentiment_score": 0.345503,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.347699",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves\u2019 launch",
      "url": "https://www.stocktitan.net/news/IMVT/immunovant-announces-pricing-of-550-million-common-stock-7ykshajkmqa8.html",
      "time_published": "20251211T060933",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant (Nasdaq: IMVT) announced the pricing of an underwritten common stock offering to raise $550 million by selling 26.2 million shares at $21.00 each. These proceeds, combined with existing cash, are expected to fund the company's operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves' disease. Roivant Sciences, the controlling stockholder, has agreed to purchase shares in the offering, which is anticipated to close on or about December 12, 2025.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919911"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.807099"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.711372"
        },
        {
          "topic": "finance",
          "relevance_score": "0.732290"
        }
      ],
      "overall_sentiment_score": 0.485587,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.462920",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "55,524 Shares in Immunovant, Inc. $IMVT Purchased by Capital Fund Management S.A.",
      "url": "https://www.marketbeat.com/instant-alerts/filing-55524-shares-in-immunovant-inc-imvt-purchased-by-capital-fund-management-sa-2025-12-06/",
      "time_published": "20251207T040326",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Capital Fund Management S.A. recently acquired 55,524 shares of Immunovant, Inc. (NASDAQ:IMVT) valued at $888,000, as institutional ownership of the stock reaches approximately 47.1%. Despite a \"Moderate Buy\" consensus from analysts with an average target price of $28.78, the company remains unprofitable with a recent EPS of -$0.73. Insiders have sold off about 57,847 shares totaling $1.31 million in the last three months, now holding 1.8% of the company.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904972"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.800072"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.744165"
        }
      ],
      "overall_sentiment_score": 0.130324,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.121526",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Two Seas Capital LP Boosts Stake in Immunovant, Inc. $IMVT",
      "url": "https://www.marketbeat.com/instant-alerts/filing-two-seas-capital-lp-boosts-stake-in-immunovant-inc-imvt-2025-12-04/",
      "time_published": "20251206T040327",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Two Seas Capital LP significantly increased its stake in Immunovant, Inc. by 37.1% in Q2, bringing its total holdings to 2,252,772 shares valued at approximately $36.0 million. This makes Immunovant the firm's 13th largest holding, despite recent insider selling and the company reporting negative earnings per share. Analysts currently rate Immunovant with a \"Moderate Buy\" consensus.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906896"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.801940"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.911949"
        }
      ],
      "overall_sentiment_score": 0.147079,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.126383",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 15,000 Shares of Stock",
      "url": "https://www.marketbeat.com/instant-alerts/insider-selling-immunovant-nasdaqimvt-director-sells-15000-shares-of-stock-2025-12-03/",
      "time_published": "20251205T040327",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Immunovant (NASDAQ:IMVT) Director Douglas Hughes sold 15,000 shares of the company's stock on December 1st for a total of $348,600, reducing his ownership by 11.05%. The stock is currently trading at $22.71 with a market cap of $3.98 billion, while analysts have a \"Moderate Buy\" rating with an average target price of $28.78. Immunovant recently missed its quarterly EPS estimates.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.900194"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.821095"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.705869"
        }
      ],
      "overall_sentiment_score": -0.212354,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.202518",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of \"Moderate Buy\" by Analysts",
      "url": "https://www.marketbeat.com/instant-alerts/immunovant-inc-nasdaqimvt-given-consensus-recommendation-of-moderate-buy-by-analysts-2025-12-04/",
      "time_published": "20251205T040327",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Immunovant, Inc. (NASDAQ:IMVT) has received a \"Moderate Buy\" consensus recommendation from analysts, with 12 firms covering the stock and an average 12-month price target of $28.78. The stock's current market capitalization is $3.98 billion, and it opened at $22.71. Despite a slight quarterly EPS miss, institutional investors hold a significant portion of the stock, while insiders have recently sold shares.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924343"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.809936"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.745070"
        }
      ],
      "overall_sentiment_score": 0.288921,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.277736",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "XTX Topco Ltd Buys New Holdings in Immunovant, Inc. $IMVT",
      "url": "https://www.marketbeat.com/instant-alerts/filing-xtx-topco-ltd-buys-new-holdings-in-immunovant-inc-imvt-2025-11-29/",
      "time_published": "20251204T080933",
      "authors": [
        "MarketBeat"
      ],
      "summary": "XTX Topco Ltd has acquired a new stake of 81,188 shares in Immunovant, Inc. (NASDAQ:IMVT), valued at approximately $1.30 million. This comes as institutional ownership in Immunovant reaches about 47.08%, despite recent insider selling. Immunovant shares are currently trading near $24.36, with analysts giving a consensus \"Moderate Buy\" rating and an average price target of $28.78.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.907554"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.828224"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.748494"
        }
      ],
      "overall_sentiment_score": 0.265339,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.232486",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immunovant, Inc. $IMVT Shares Acquired by Geode Capital Management LLC",
      "url": "https://www.marketbeat.com/instant-alerts/filing-immunovant-inc-imvt-shares-acquired-by-geode-capital-management-llc-2025-11-28/",
      "time_published": "20251128T080946",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Geode Capital Management LLC significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 9.1% in the second quarter, valuing its holdings at over $29 million. Other institutional investors like Vanguard, T. Rowe Price, and Baker BROS. Advisors also grew their positions, contributing to approximately 47.08% institutional ownership. Despite insider selling and a recent EPS miss, analysts have a \"Moderate Buy\" consensus rating with a target price of $28.78.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935033"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.835120"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.734657"
        }
      ],
      "overall_sentiment_score": -0.026659,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.147195",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JPM",
          "relevance_score": "0.618132",
          "ticker_sentiment_score": "-0.165380",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TROW",
          "relevance_score": "0.648556",
          "ticker_sentiment_score": "0.227927",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.591526",
          "ticker_sentiment_score": "-0.165516",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Have Insiders Sold Immunovant Shares Recently?",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/have-insiders-sold-immunovant-shares-recently-2",
      "time_published": "20251126T090909",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Immunovant Inc. (NASDAQ:IMVT) has seen recent insider selling, with the COO divesting US$298k worth of shares and another insider selling US$365k over the last year. Despite these sales, the amounts represent a small percentage of their total holdings. The article highlights that insiders haven't bought any shares in the past year, suggesting a cautious stance, though their overall ownership is still enough to imply alignment with shareholders.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948439"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.848961"
        }
      ],
      "overall_sentiment_score": -0.285484,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.280741",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Have Insiders Sold Immunovant Shares Recently?",
      "url": "https://www.sahmcapital.com/news/content/have-insiders-sold-immunovant-shares-recently-2025-11-23",
      "time_published": "20251124T040327",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Recent insider transactions at Immunovant (NASDAQ:IMVT) show that the Chief Operating Officer divested US$298k worth of shares, and another insider sold US$365k worth of shares below the current price within the last year. While insiders own 0.8% of the company, no insider buying has occurred in the recent past, suggesting a need for careful consideration before investing.",
      "banner_image": "https://images.simplywall.st/asset/chart/592774643-insider-trading-volume-1-dark-2/1763903678279",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.924453"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.742179"
        }
      ],
      "overall_sentiment_score": -0.29165,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.260153",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Immunovant Inc expected to post a loss of 72 cents a share - Earnings Preview",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3WJ2EC:0-immunovant-inc-expected-to-post-a-loss-of-72-cents-a-share-earnings-preview/",
      "time_published": "20251111T080933",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant Inc (IMVT) is projected to report no change in quarterly revenue and a loss of 72 cents per share for the period ending September 30, 2025. Analysts currently rate the shares as \"buy\" with a median 12-month price target of $44.00, representing a 46.2% increase from its last closing price. The company has a mixed history of beating and missing earnings estimates in previous quarters.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.930232"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.730622"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.602072"
        }
      ],
      "overall_sentiment_score": -0.224724,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.206831",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT)",
      "url": "https://seekingalpha.com/article/4836470-immunovant-takeover-buzz-imvt-1402-promise-and-why-im-staying-neutral",
      "time_published": "20251031T140100",
      "authors": [
        "Stephen Ayers"
      ],
      "summary": "Immunovant (IMVT) remains a high-risk, high-reward investment, heavily dependent on the success of its next-generation candidate, IMVT-1402, which currently shows promising Phase 1 data but lacks direct patient efficacy. The company's valuation already incorporates significant future success, creating persistent cash burn and dilution risks until key efficacy readouts in 2026-2027. The author is maintaining a Hold rating due to the outweighing downside risks until more robust clinical data becomes available.",
      "banner_image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1434437996/image_1434437996.jpg?io=getty-c-w630",
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904873"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.820352"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.737746"
        }
      ],
      "overall_sentiment_score": -0.088934,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.084205",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Truist Securities initiates Immunovant stock with Hold rating, $16 target - Investing.com",
      "url": "https://www.investing.com/news/analyst-ratings/truist-securities-initiates-immunovant-stock-with-hold-rating-16-target-93CH-4285464",
      "time_published": "20251014T110823",
      "authors": [],
      "summary": "Truist Securities has initiated coverage on Immunovant stock with a Hold rating and a $16 target price. This analyst action provides an initial valuation perspective for investors interested in Immunovant.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.831882"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.732922"
        }
      ],
      "overall_sentiment_score": 0.030829,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.340239",
          "ticker_sentiment_score": "0.013632",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jay Stout Sells 1,585 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat",
      "url": "https://www.marketbeat.com/instant-alerts/jay-stout-sells-1585-shares-of-immunovant-nasdaqimvt-stock-2025-10-10/",
      "time_published": "20251011T210053",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Immunovant CTO Jay Stout sold 1,585 shares of IMVT stock at an average price of $16.30, decreasing his ownership by 0.77%. The company's shares traded down 2.6% to $17.03, with a market cap of $2.97 billion, and reported better-than-expected EPS of ($0.60). Institutional investors hold 47.08% of the stock, while analysts have issued updated ratings and price targets.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.911111"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725419"
        }
      ],
      "overall_sentiment_score": 0.021984,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.309150",
          "ticker_sentiment_score": "0.026086",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Immunovant (NASDAQ:IMVT) Insider Michael Geffner Sells 1,272 Shares",
      "url": "https://www.marketbeat.com/instant-alerts/immunovant-nasdaqimvt-insider-michael-geffner-sells-1272-shares-2025-10-10/",
      "time_published": "20251011T210053",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Immunovant insider Michael Geffner sold 1,272 shares of the company's stock, valued at $20,733.60, reducing his ownership by 0.57%. The company's shares traded down 2.6% to $17.03, giving it a market capitalization of $2.97 billion. Institutional investors hold 47.08% of Immunovant's stock, and the company recently reported an earnings per share of ($0.60), beating consensus estimates.",
      "banner_image": "https://www.marketbeat.com/logos/immunovant-inc-logo-1200x675.png?v=20221128150716",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.903509"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.836472"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.740737"
        }
      ],
      "overall_sentiment_score": 0.019391,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.306646",
          "ticker_sentiment_score": "0.049353",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm",
      "url": "https://www.businesswire.com/news/home/20250827079251/en/IMVT-Investors-Have-Opportunity-to-Join-Immunovant-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm",
      "time_published": "20250827T000000",
      "authors": [],
      "summary": "The Schall Law Firm has announced an investigation into Immunovant, Inc. (NASDAQ: IMVT) regarding potential securities law violations due to false or misleading statements. Shareholders who suffered losses are encouraged to contact the firm to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.913733"
        },
        {
          "topic": "finance",
          "relevance_score": "0.889099"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.712163"
        }
      ],
      "overall_sentiment_score": -0.616227,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.626854",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm",
      "url": "https://www.prnewswire.com/news-releases/imvt-investigation-alert-investigation-launched-into-private-placement-transaction-by-immunovant-inc-and-attorneys-encourage-investors-to-contact-law-firm-302468805.html",
      "time_published": "20250529T171000",
      "authors": [],
      "summary": "Robbins Geller Rudman & Dowd LLP has launched an investigation into potential breaches of fiduciary duty by directors and officers of Immunovant, Inc. and its controlling stockholder, Roivant Sciences Ltd. This investigation concerns Immunovant's January 2025 private placement transaction where Roivant purchased nearly 16.9 million shares at a significant discount, resulting in a benefit of nearly $60 million to Roivant at the expense of other Immunovant shareholders. Investors are encouraged to contact the law firm for more information.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": -0.613159,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.735006",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "RVTY",
          "relevance_score": "0.643476",
          "ticker_sentiment_score": "-0.506869",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024",
      "url": "https://www.quiverquant.com/news/Immunovant%2C+Inc.+Reports+Progress+on+IMVT-1402+Development+and+Financial+Results+for+Fiscal+Q3+2024",
      "time_published": "20250206T114000",
      "authors": [
        "NULL"
      ],
      "summary": "Immunovant, Inc. reported significant progress on its lead asset IMVT-1402, with six Investigational New Drug applications cleared and pivotal studies enrolling for Graves' disease and rheumatoid arthritis. The company also announced its fiscal third-quarter 2024 financial results, including an increased net loss and research and development expenses, while maintaining a strong cash position of approximately $825 million including recent private placement proceeds. Key milestones include expected top-line results from batoclimab trials by March 2025 and treatment-free remission data for Graves' disease by summer 2025, with plans to initiate trials for IMVT-1402 across ten indications by March 2026.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925847"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.827274"
        }
      ],
      "overall_sentiment_score": 0.276766,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.978608",
          "ticker_sentiment_score": "0.269259",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm",
      "url": "https://www.wate.com/business/press-releases/cision/20250124NY03911/kuehn-law-encourages-investors-of-immunovant-inc-to-contact-law-firm",
      "time_published": "20250124T133400",
      "authors": [],
      "summary": "Kuehn Law, PLLC is investigating Immunovant, Inc. (NASDAQ: IMVT) regarding potential breaches of fiduciary duties by its officers and directors, specifically concerning self-dealing. The firm is encouraging long-term shareholders to contact them to discuss potential damages and corporate governance reforms, emphasizing that participation is free and contributes to market integrity.",
      "banner_image": null,
      "source": "WATE 6 On Your Side",
      "category_within_source": "General",
      "source_domain": "WATE 6 On Your Side",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.849068"
        },
        {
          "topic": "finance",
          "relevance_score": "0.747016"
        }
      ],
      "overall_sentiment_score": -0.542353,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.522399",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT)",
      "url": "https://seekingalpha.com/article/4746681-immunovant-continued-fcrn-targeting-with-imvt-1402-pivotal-study",
      "time_published": "20241227T105000",
      "authors": [
        "Terry Chrisomalis"
      ],
      "summary": "Immunovant plans to initiate a pivotal registration study for IMVT-1402 in Graves' Disease by the end of 2024, with additional trials for other autoimmune disorders by March 2025. IMVT-1402 is noted for its deeper IgG suppression without the LDL cholesterol increase seen with Batoclimab. Investors are cautioned about Immunovant's 12-month cash runway, suggesting a potential need for a cash raise in 2025, while the Graves' Disease market is projected to reach $614.6 million by 2033.",
      "banner_image": null,
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.813094"
        }
      ],
      "overall_sentiment_score": 0.112005,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.146271",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Prevent Blindness declares 5th annual Thyroid Eye Disease Awareness Week",
      "url": "https://www.ophthalmologytimes.com/view/prevent-blindness-declares-5th-annual-thyroid-eye-disease-awareness-week",
      "time_published": "20241115T000000",
      "authors": [
        "David Hutton"
      ],
      "summary": "Prevent Blindness has declared November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week to raise public and professional awareness of TED's symptoms, impact on vision and mental health, and new treatment options. The week is supported by pharmaceutical companies and will feature educational resources and expert-led discussions. Experts emphasize early detection and anticipate significant advancements in TED treatment in the coming years, with emerging therapies targeting immune modulation.",
      "banner_image": null,
      "source": "Ophthalmology Times",
      "category_within_source": "General",
      "source_domain": "Ophthalmology Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925806"
        }
      ],
      "overall_sentiment_score": 0.310074,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.307912",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immunovant\u2019s Confidence In Graves\u2019 Disease Builds",
      "url": "https://insights.citeline.com/SC150870/Immunovants-Confidence-In-Graves-Disease-Builds/",
      "time_published": "20240909T000000",
      "authors": [
        "Jessica Merrill"
      ],
      "summary": "Immunovant announced positive data regarding its research in Graves' disease. This development builds confidence in the company's efforts within the immune disorders sector. The news highlights Immunovant's continued focus on clinical trials for rare diseases.",
      "banner_image": null,
      "source": "Citeline News & Insights",
      "category_within_source": "General",
      "source_domain": "Citeline News & Insights",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900786"
        }
      ],
      "overall_sentiment_score": 0.531499,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.528498",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024",
      "url": "https://www.stocktitan.net/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-sa2862y39qc4.html",
      "time_published": "20240529T160100",
      "authors": [],
      "summary": "Immunovant (Nasdaq: IMVT) reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, alongside significant corporate updates. The company plans to initiate 4-5 potentially registrational studies for its lead asset IMVT-1402 by March 31, 2025, and provided updates on its batoclimab trials, emphasizing a strategic shift towards IMVT-1402. Financially, Immunovant reported a net loss of $75.3 million for Q4 and $259.3 million for the full fiscal year, with a cash position of approximately $635 million as of March 31, 2024.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.919036"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.833823"
        }
      ],
      "overall_sentiment_score": 0.21189,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.221616",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SPAC To Merge With SPAC That Merged With Spinoff From Company The First SPAC Is Merging With",
      "url": "https://dealbreaker.com/2021/05/spac-to-merge-with-spac-of-course",
      "time_published": "20210521T203144",
      "authors": [
        "Jon Shazar"
      ],
      "summary": "This article discusses Roivant Sciences' complex plan to go public through a blank-check merger, which involves merging with a SPAC, Montes Archimedes Acquisition Corp., and then merging with Immunovant, a company it previously spun off via a SPAC deal. The author notes the unusual nature of this \"self-merging\" SPAC transaction, highlighting its complexity and the premium being paid for Immunovant based on \"non-public\" information. This deal is presented as a culmination of the SPAC boom, showcasing an intricate financial maneuver.",
      "banner_image": "https://creativecommons.org/licenses/by-sa/4.0",
      "source": "Dealbreaker",
      "category_within_source": "General",
      "source_domain": "Dealbreaker",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.935860"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.826582"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.613229"
        }
      ],
      "overall_sentiment_score": 0.31812,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "0.931929",
          "ticker_sentiment_score": "0.306593",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation",
      "url": "https://www.globenewswire.com/news-release/2019/12/19/1962769/0/en/Immunovant-Sciences-Ltd-Closes-Transaction-with-Health-Sciences-Acquisitions-Corporation.html",
      "time_published": "20191219T080000",
      "authors": [],
      "summary": "Immunovant, Inc., formerly Health Sciences Acquisitions Corporation (HSAC), announced the closing of its business combination with Immunovant Sciences Ltd. The combined company will trade on Nasdaq under the ticker symbol \"IMVT\" starting December 19, 2019, with over $100 million in proceeds supporting key IMVT-1401 pipeline programs. Immunovant also reiterated guidance for upcoming data releases from its ongoing and planned Phase 2 clinical trials for various autoimmune diseases.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.924806"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.936053"
        },
        {
          "topic": "finance",
          "relevance_score": "0.642399"
        }
      ],
      "overall_sentiment_score": 0.49814,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IMVT",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.488550",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}